1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Recurrent Glioblastoma Multiforme (GBM) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

SUMMARY
DelveInsight’s, “ Recurrent Glioblastoma Multiforme (GBM)- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- A snapshot of the global Market therapeutics scenario for Recurrent Glioblastoma Multiforme (GBM).
- A review of the marketed products under prescription for Recurrent Glioblastoma Multiforme (GBM), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Recurrent Glioblastoma Multiforme (GBM) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Recurrent Glioblastoma Multiforme (GBM) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Recurrent Glioblastoma Multiforme (GBM) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Recurrent Glioblastoma Multiforme (GBM) drugs.
- Coverage of Recurrent Glioblastoma Multiforme (GBM) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Recurrent Glioblastoma Multiforme (GBM) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Recurrent Glioblastoma Multiforme (GBM).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Recurrent Glioblastoma Multiforme (GBM).
- API intelligence over marketed drugs for Recurrent Glioblastoma Multiforme (GBM) and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Recurrent Glioblastoma Multiforme (GBM).
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Recurrent Glioblastoma Multiforme (GBM) Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information


List of Tables

Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2014
Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status, 2014
Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Recurrent Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales (in million USD), 2014
Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers, Global, 2014
Recurrent Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Recurrent Glioblastoma Multiforme (GBM), 2014?


List of Figures

Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2014
Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Recurrent Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales (in million USD), 2014
Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Brain Cancer: Analytical Tool

Brain Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

Glioblastoma Multiforme-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Glioblastoma Multiforme - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the US

  • November 2016
    74 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics and Therapy Market in the US - Forecast

  • November 2016
    52 pages
  • Cancer  

    Therapy  

  • United States  

View report >

Related Market Segments :

Brain Cancer

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.